(NewsDirect)
ORLANDO, FL / PlatoData via 500NewsWire / July 27, 2023 / Nutriband Inc. (the“Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermalpharmaceutical products, today announced the launch of its consumersports recovery tape brand, Active Intelligence AI Tape (“AITape”), with products now available for purchase on Amazon and Activeintell.com .
AI Tape is designed tocombine many of the traditional benefits of kinesiology tape with theaddition of soothing and therapeutic ingredients held in suspensionwith a proprietary adhesive mix.
“We are very excited for the launch of our AITape brand, our first products targeting the consumer market,”stated Gareth Sheridan, Nutriband CEO. “Consumers looking to takeadvantage of the sports recovery benefits provided by AI Tape canpurchase products, including our Active Intelligence AI KinesiologyTape, on Amazon or through our Active Intelligence website.”
AI Tape is manufacturedin the USA at the Company's Pocono Pharmaceutical facility inNorth Carolina.
About Nutriband Inc.
We are primarily engaged in the development of aportfolio of transdermal pharmaceutical products. Our lead productunder development is an abuse deterrent fentanyl patch incorporatingour AVERSA™ abuse deterrence technology. AVERSA™ technology can beincorporated into any transdermal patch to prevent the abuse, misuse,diversion, and accidental exposure of drugs with abusepotential.
TheCompany's website is https://www.nutriband.com/ . Anymaterial contained in or derived from the Company's websites orany other website is not part of this press release.
Forward-LookingStatements
Certain statements contained in this press release, including,without limitation, statements containing the words‘'believes," "anticipates," "expects" andwords of similar import, constitute "forward-lookingstatements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such forward-looking statements involveboth known and unknown risks and uncertainties. The Company'sactual results may differ materially from those anticipated in itsforward-looking statements as a result of a number of factors,including those including the Company's ability to develop itsproposed abuse deterrent fentanyl transdermal system and otherproposed products, its ability to obtain patent protection for itsabuse technology, its ability to obtain the necessary financing todevelop products and conduct the necessary clinical testing, itsability to obtain Federal Food and Drug Administration approval tomarket any product it may develop in the United States and to obtainany other regulatory approval necessary to market any product in othercountries, including countries in Europe, its ability to market anyproduct it may develop, its ability to create, sustain, manage orforecast its growth; its ability to attract and retain key personnel;changes in the Company's business strategy or development plans;competition; business disruptions; adverse publicity andinternational, national and local general economic and marketconditions and risks generally associated with an undercapitalizeddeveloping company, as well as the risks contained under "RiskFactors" and "Management's Discussion and Analysis ofFinancial Condition and Results of Operations" in theCompany's Form S-1, Form 10-K for the year ended January 31, 2023and Forms 10-Q, and the Company's other filings with theSecurities and Exchange Commission. Except as required by applicablelaw, we undertake no obligation to revise or update anyforward-looking statements to reflect any event or circumstance thatmay arise after the date hereof.
ContactDetails
David Zazoff - MDM Worldwide
Copyright (c) 2023 TheNewswire - All rights reserved.